External Qi of Yan Xin Qigong induces apoptosis and inhibits migration and invasion of estrogen-independent breast cancer cells through suppression of akt/NF-κB signaling

Cellular Physiology and Biochemistry

Volumn 25, Issue 2-3, 2010, Pages 263-270

  Yan, Xin ^a,b   Shen, Hua ^b   Jiang, Hongjian ^c   Hu, Dan ^d   Zhang, Chengsheng ^e   Wang, Jun ^b   Wu, Xinqi ^c,d  

^a Chongqing Institute of Traditional Chinese Medicine   (China)

^b New Medical Science Research Institute   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Akt; Apoptosis; Breast cancer; External Qi of Yan Xin Qigong; Metastasis; NF B

Indexed keywords

CHINESE DRUG; EXTERNAL QI OF YAN XIN QIGONG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INVASION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 76249103204     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276560     Document Type: Article

References (58)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
3. Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-717.
4. Haefner B: NF-κB: arresting a major culprit in cancer. Drug Discov Today 2002;7:653-663.
5. Karin M, Cao MY, Greten FR, Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
6. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-10985.
7. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW: Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337.
8. Dillon RL, White DE, Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-1345.
9. Woodgett JR: Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005;17:150-157.
10. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB: The nuclear factor κB (NF-κB): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci USA 2001;98:10386-10391.
11. Rahman KW, Sarkar FH: Inhibition of nuclear translocation of nuclear factor-κB contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 2005;65:364-371.
12. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-1148.
13. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB: N-(4-hydroxy-phenyl) retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through downregulation of IκBα kinase and nuclear factor κB-regulated gene products. Cancer Res 2005;65:9555-9565.
14. Sliva D, Rizzo MT, English D: Phosphatidylinositol 3-kinase and NF-kB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator (uPA). J Biol Chem 2002;277:3150-3157.
15. Srivastava SK, Singh SV: Cell cycle arrest, apoptosis induction and inhibition of nuclear factor κB activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis 2004;25:1701-1709.
16. Kuo PL, Hsu YL, Lin TC, Tzeng WS, Chen Y Y, Lin CC: Rugosin E, an ellagitannin, inhibits MDA-MB-231 human breast cancer cell proliferation and induces apoptosis by inhibiting nuclear factor-κB signaling pathway. Cancer Lett 2007;248:280-291.
17. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D: Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/ NF-kB signaling. Nutr Cancer 2004;49:209-216.
18. Liang k, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2003;2:353-360.
19. Rahman KW, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip AP, Sakr WA, Raz A: Inactivation of NF-κB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:2757-2765.
20. Sliva D, Jedinak A, Kawasaki J, Harvey K, Slivova V: Phellinus linteus suppresses growth, angiogenesis and invasive behavior of breast cancer cells through the inhibition of AKT signaling. Br J Cancer 2008;98:1348-1356.
21. Yan X, Shen H, Jiang H, Zhang C, Hu D, Wang J, Wu X: External Qi of Yan Xin Qigong differentially regulates the Akt and extracellular signal-regulated kinase pathways and is cytotoxic to cancer cells but not to normal cells. Int J Biochem Cell Biol 2006;38:2102-2113.
22. Yan X, Shen H, Jiang H, Zhang C, Hu D, Wang J, Wu X: External Qi of Yan Xin Qigong induces G2/M arrest and apoptosis of androgen-independent prostate cancer cells by inhibiting Akt and NF-κB pathways. Mol Cell Biochem 2008;310:227-234.
23. Yan X, Shen H, Zaharia M, Wang J, Wolf D, Li F, Cao W: Involvement of phosphatidylinositol 3-kinase and insulin-like growth factor-I in YXLST-mediated neuroprotection. Brain Res 2004;1006:198-206.
24. Fong YH: Yan Xin Qigong informative product: Qi nutrition powder; in International Yan Xin Qigong Association (ed): Yan Xin Qigong Collectanea. Quebec, Les Editions LOTUS Publishers of Canada, 1997, vol 6, pp 299-318.
25. Lu Z: Scientific Qigong exploration: the wonders and mysteries of Qi. Malvern, Pennsylvania, Amber Leaf Press, 1997.
26. Ming Z: The new frontiers of modern sciences: an introduction to Yan Xin Qigong. Beijing, Xinhua Press, 1988.
27. Wang R, Zhu R: Yan Xin Qigong nutrition powder: report of nine cases; in International Yan Xin Qigong Association (ed): Yan Xin Qigong Collectanea. Quebec, Les Editions LOTUS Publishers of Canada, 1997, vol 1, pp 266-271.
28. Zhang ZW, Zhao JX, Zhang XR. Yan Xin Qigong nutrition powder: clinical report; in International Yan Xin Qigong Association (ed): Yan Xin Qigong Collectanea. Quebec, Les Editions LOTUS Publishers of Canada, 1997, vol 1, pp 319-329.
29. Li S, Sun M, Dai Z, Zhang P, Meng G, Liu Z, Ma Q, Zhu Q, Wang Q, Zhang L, Shan L, Sun Y, Hu Y, Chen Y, Pang Y, Wang G, Hao X, Lu A, Fan X, Yan X: Experimental studies on the feasibility of improving industrial strains with external Qi treatment. Nat J 1990;13:791-801.
30. Yan X, Zheng C, Zou G, Lu Z: Observations of the effects of external Qi on the ultraviolet absorption of nucleic acids. Nat J 1988;11:647-649.
31. Yan X, Zhao N, Yin C, Lu Z: The effect of external Qi on liposome phase behavior. Nat J 1988;11:572-576.
32. Yan X, Lin H, Li H, Traynor-Kaplan A, Xia Z, Lu F, Fang Y, Dao M: Structural and property changes in certain materials influenced by the external Qi of Qigong. Mater Res Innov 1999;2:349-359.
33. Yan X, Lu F, Jiang H, Wu X, Cao W, Xia Z, Dao M, Lin H: Certain manifestation and effects of external Qi of Yan Xin life science and technology. J Sci Explor 2002;16:381-411.
34. Yan X, Xia ZQ, Shen H, Traynor-Kaplan A: External Qi of Yan Xin life science and technology can revive or suppress enzyme activity of phosphatidylinositol 3-kinase. Bull Sci Tech Soc 2002;22:403-406.
35. Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C: Clonogenic assay of cells in vitro. Nature Protocols 2006;1:2315-2319.
36. Hwang HC, Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-2786.
37. Weinberg RA: The Retinoblastoma Protein and Cell Cycle Control. Cell 1995;81:323-330.
38. Aggarwal BB: Nuclear factor-κB: the enemy within, Cancer Cell 2004;6:203-208.
39. Dixit V, Mak TW: NF-κB signaling. Many roads lead to Madrid. Cell 2002;111:615-619.
40. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-7492.
41. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH: Inactivation of nuclear factor κB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65:6934-6942.
42. Pan Q, Bao LW, Merajver SD: Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NF-κB signaling cascade. Mol Cancer Res 2003;1:701-706.
43. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X: Biochemical pathways of caspase activation during apoptosis. Ann Rev Cell Dev Biol 1999;15:269-290.
44. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005;11:7490-7498.
45. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW: Discovery of potent antagonists of the anti-apoptotic protein XIAP for the treatment of cancer. J Med Chem 2004;47:4417-4426.
46. Finucane DM, Bossy-Wetzel E, Waterhouse NJ, Cotter TG, Green DR: Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by BclxL. J Biol Chem 1999;274:2225-2233.
47. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G: Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 1998;95:4386-4391.
48. Willis SN, Adams JM: Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005;17:617-625.
49. Kim R, Emi M, Tanabe K: Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006;57:545-553. (Pubitemid 43237837)
50. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ: Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005;56:46-54.
51. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH: Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006;66:4952-4960.
52. Ciardiello F: Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1:221-234.
53. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M: Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006;13:3483-3492.
54. Nyati MK, Morgan MA, Feng FY, Lawrence TS: Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-885.
55. Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-5272.
56. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J: Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treatment Reviews 2009;35:354-363.
57. Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB: Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome C release. Cancer Research 2002;62:488-496.
58. Yan X, Fong YH, Wolf G, Wolf D, Cao W: Protective effect of XY99-5038 on hydrogen peroxide induced cell death in cultured retinal neurons. Life Sci 2001;69:289-299.